Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Current Deferred Revenue: 2014-2018

Historic Current Deferred Revenue for ImmunityBio (IBRX) over the last 3 years, with Dec 2018 value amounting to $598,000.

  • ImmunityBio's Current Deferred Revenue rose 15.00% to $598,000 in Q4 2018 from the same period last year, while for Dec 2018 it was $598,000, marking a year-over-year increase of 15.00%. This contributed to the annual value of $598,000 for FY2018, which is 15.00% up from last year.
  • Latest data reveals that ImmunityBio reported Current Deferred Revenue of $598,000 as of Q4 2018, which was up 3.64% from $577,000 recorded in Q3 2018.
  • ImmunityBio's Current Deferred Revenue's 5-year high stood at $598,000 during Q4 2018, with a 5-year trough of $5,000 in Q4 2015.
  • Its 3-year average for Current Deferred Revenue is $465,444, with a median of $520,000 in 2017.
  • In the last 5 years, ImmunityBio's Current Deferred Revenue slumped by 99.04% in 2015 and then surged by 3,840.00% in 2016.
  • ImmunityBio's Current Deferred Revenue (Quarterly) stood at $521,000 in 2014, then tumbled by 99.04% to $5,000 in 2015, then spiked by 3,840.00% to $197,000 in 2016, then surged by 163.96% to $520,000 in 2017, then increased by 15.00% to $598,000 in 2018.
  • Its Current Deferred Revenue stands at $598,000 for Q4 2018, versus $577,000 for Q3 2018 and $558,000 for Q2 2018.